Home › Biliary Tract Cancer › Washington › Seattle
Biliary Tract Cancer clinical trials in Seattle, WA
4 studies for Biliary Tract Cancer are looking for participants at sites in and around Seattle (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
RecruitingPhase 3
- Fred Hutchinson Cancer Center Clinic (Site 122), Seattle
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
RecruitingPhase 3
- Research Site, Seattle
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
RecruitingPhase 1/2
- Avenzo Therapeutics Recruiting Site, Seattle
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
RecruitingPhase 2
- University of Washington School of Medicine, Seattle
Biliary Tract Cancer trials in other cities
- Houston, TX18 studies
- Los Angeles, CA11 studies
- Boston, MA11 studies
- New York City, NY10 studies
- Nashville, TN9 studies
- San Antonio, TX8 studies
- Baltimore, MD8 studies
- Washington, DC7 studies
- Arlington, VA7 studies
- Pittsburgh, PA7 studies
- Cleveland, OH6 studies
- Baldwin Park, CA6 studies
Other studies in Seattle
- Non-Small Cell Lung Cancer53 studies
- Cancer (all types)49 studies
- Prostate Cancer42 studies
- Acute Myeloid Leukemia40 studies
- Breast Cancer39 studies
- Metastatic Cancer39 studies
- Colorectal Cancer34 studies
- Lung Cancer33 studies
- Ovarian Cancer30 studies
- Multiple Myeloma22 studies
- Myelodysplastic Syndromes21 studies
- Acute Lymphoblastic Leukemia21 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.